1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Daewoong pharmaceutical Co.,Ltd

Daewoong pharmaceutical Co.,Ltd

069620.KS
Daewoong pharmaceutical Co.,LtdKR flagKorea Exchange
134,500.00
KRW
+1,200.00
- -
1.55TMarket Cap

Total Valuation

Daewoong pharmaceutical Co.,Ltd carries a market capitalization of 1.55T, placing it among publicly traded companies globally. Its enterprise value stands at 2.70T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.55T
Enterprise Value2.70T

Share Statistics

Daewoong pharmaceutical Co.,Ltd currently has 11.51M shares outstanding.

Shares Outstanding11.51M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Daewoong pharmaceutical Co.,Ltd trades at a trailing price-to-earnings ratio of 9.21. The price-to-sales ratio is 1.16, and the price-to-book ratio stands at 2.09.

PE Ratio9.21
PS Ratio1.16
PB Ratio2.09
P/TBV Ratio2.39
P/FCF Ratio3.92
P/OCF Ratio11.27

Enterprise Valuation

On an enterprise value basis, Daewoong pharmaceutical Co.,Ltd trades at an EV/EBITDA multiple of 8.00 and an EV/FCF ratio of 5.68. The EV/Sales ratio of 1.70 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.00 provides insight into valuation relative to core operating earnings.

EV / Sales1.70
EV / EBITDA8.00
EV / EBIT8.00
EV / FCF5.68

Financial Position

Daewoong pharmaceutical Co.,Ltd maintains a current ratio of 1.12, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 78.01, indicating elevated leverage, while an interest coverage ratio of 53.77 demonstrates strong ability to service its debt obligations.

Current Ratio1.12
Quick Ratio0.26
Debt / Equity78.01
Debt / EBITDA2.67
Interest Coverage53.77

Financial Efficiency

Daewoong pharmaceutical Co.,Ltd posts a return on equity of 25.61 and a return on invested capital of 18.52.

Return on Equity (ROE)25.61
Return on Assets (ROA)9.00
Return on Invested Capital (ROIC)18.52
Return on Capital Employed (ROCE)12.26
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.62

Taxes

Over the trailing twelve months, Daewoong pharmaceutical Co.,Ltd has paid 2.43B in income taxes, reflecting an effective tax rate of 1.21.

Income Tax2.43B
Effective Tax Rate1.21

Stock Price Statistics

Daewoong pharmaceutical Co.,Ltd's stock has declined approximately -14.65736% over the past 52 weeks. The 50-day moving average sits at 130,906.00, while the 200-day moving average is 153,436.50.

Beta (5Y)N/A
52-Week Price Change-14.65736%
50-Day Moving Average130,906.00
200-Day Moving Average153,436.50
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Daewoong pharmaceutical Co.,Ltd generated 1.59T in revenue and converted that into 199.86B in net income, yielding earnings per share of 17,263.72. EBITDA reached 337.52B, while operating income came in at 337.52B.

Revenue1.59T
Gross Profit820.64B
Operating Income337.52B
Pretax Income201.07B
Net Income199.86B
EBITDA337.52B
EBIT337.52B
Earnings Per Share (EPS)17,263.72

Balance Sheet

Daewoong pharmaceutical Co.,Ltd holds 168.03B in cash and equivalents against 900.43B in total debt, resulting in a net debt position of 734.38B. Total book value stands at 881.43B, with working capital of 81.13B providing operational flexibility.

Cash & Cash Equivalents168.03B
Total Debt900.43B
Net Debt734.38B
Equity (Book Value)881.43B
Book Value Per Share76,603.92
Working Capital81.13B

Cash Flow

Daewoong pharmaceutical Co.,Ltd produced 163.33B in operating cash flow over the past twelve months. After subtracting -305.88B in capital expenditures, free cash flow totaled -142.55B - equivalent to -12,388.88 per share.

Operating Cash Flow163.33B
Capital Expenditures-305.88B
Free Cash Flow-142.55B
FCF Per Share-12,388.88

Margins

Daewoong pharmaceutical Co.,Ltd operates with a gross margin of 51.54, reflecting its pricing power and cost economics. The operating margin of 21.20 and net profit margin of 12.55 provide insight into operational efficiency.

Gross Margin51.54
Operating Margin21.20
Pretax Margin12.63
Profit Margin12.55
EBITDA Margin21.20

Dividends & Yields

The company's payout ratio of 1.09 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share186.76
Dividend YieldN/A
Payout Ratio1.09
Shareholder Yield-11.75
FCF Yield25.49

Stock Splits

Daewoong pharmaceutical Co.,Ltd's most recent stock split took place on December 27, 2012 with a 100:103 split ratio.

Last Split Date12/27/2012
Split Ratio100:103

Scores

Daewoong pharmaceutical Co.,Ltd posts an Altman Z-Score of 2.79, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.79